GlobeNewswire: RECORDATI Contains the last 10 of 220 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:27:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/03/23/2197378/0/it/RECORDATI-I-RISULTATI-POSITIVI-DELLO-STUDIO-DI-FASE-III-LINC-4-PRESENTATI-AL-CONGRESSO-ANNUALE-DELLA-ENDOCRINE-SOCIETY-RICONFERMANO-L-EFFICACIA-E-LA-SICUREZZA-DI-ISTURISA-OSILODROS.html?f=22&fvtc=4&fvtv=31314RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER IL TRATTAMENTO DELLA MALATTIA DI CUSHING2021-03-23T08:00:39Z<![CDATA[RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER IL TRATTAMENTO DELLA MALATTIA DI CUSHING]]>https://www.globenewswire.com/news-release/2021/03/23/2197378/0/en/RECORDATI-POSITIVE-RESULTS-FROM-THE-PHASE-III-LINC-4-STUDY-PRESENTED-AT-THE-ENDOCRINE-SOCIETY-S-ANNUAL-MEETING-REINFORCE-THE-EFFICACY-AND-SAFETY-OF-ISTURISA-OSILODROSTAT-IN-CUSHING.html?f=22&fvtc=4&fvtv=31314RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE2021-03-23T08:00:39Z<![CDATA[RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE]]>https://www.globenewswire.com/news-release/2021/02/22/2179441/0/it/RECORDATI-RISULTATI-PRELIMINARI-2020-CONFERMANO-LA-CONTINUA-CRESCITA-DEGLI-UTILI-OPERATIVI-E-UTILI-NETTI-EBITDA-4-7-E-UTILE-NETTO-RETTIFICATO-7-3.html?f=22&fvtc=4&fvtv=31314RECORDATI: RISULTATI PRELIMINARI 2020 CONFERMANO LA CONTINUA CRESCITA DEGLI UTILI OPERATIVI E UTILI NETTI. EBITDA +4,7% E UTILE NETTO RETTIFICATO +7,3%2021-02-22T12:20:12Z<![CDATA[RECORDATI: RISULTATI PRELIMINARI 2020 CONFERMANO LA CONTINUA CRESCITA DEGLI UTILI OPERATIVI E UTILI NETTI. EBITDA +4,7% E UTILE NETTO RETTIFICATO +7,3%]]>https://www.globenewswire.com/news-release/2021/02/22/2179441/0/en/RECORDATI-PRELIMINARY-2020-RESULTS-CONFIRM-CONTINUED-GROWTH-OF-OPERATING-INCOME-AND-NET-INCOME-EBITDA-4-7-AND-ADJUSTED-NET-INCOME-7-3.html?f=22&fvtc=4&fvtv=31314RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%.2021-02-22T12:20:12Z<![CDATA[RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%.]]>https://www.globenewswire.com/news-release/2021/01/29/2166785/0/en/RECORDATI-LICENSE-OBTAINED-FOR-THE-COMMERCIALIZATION-OF-ELIGARD-IN-EUROPE-AND-OTHER-COUNTRIES.html?f=22&fvtc=4&fvtv=31314RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES2021-01-29T17:11:31Z<![CDATA[RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES]]>https://www.globenewswire.com/news-release/2021/01/29/2166785/0/it/RECORDATI-OTTENUTA-LICENZA-PER-LA-COMMERCIALIZZAZIONE-DI-ELIGARD-IN-EUROPA-E-ALTRI-PAESI.html?f=22&fvtc=4&fvtv=31314RECORDATI: OTTENUTA LICENZA PER LA COMMERCIALIZZAZIONE DI ELIGARD® IN EUROPA E ALTRI PAESI2021-01-29T17:11:31Z<![CDATA[RECORDATI: OTTENUTA LICENZA PER LA COMMERCIALIZZAZIONE DI ELIGARD® IN EUROPA E ALTRI PAESI]]>https://www.globenewswire.com/news-release/2020/11/30/2136491/0/it/RECORDATI-ACCETTATA-DALLA-EUROPEAN-MEDICINES-AGENCY-LA-PRESENTAZIONE-DELLA-RICHIESTA-DI-AUTORIZZAZIONE-ALL-IMMISSIONE-IN-COMMERCIO-PER-ARS-1-SPRAY-NASALE-A-BASE-DI-EPINEFRINA.html?f=22&fvtc=4&fvtv=31314RECORDATI: ACCETTATA DALLA EUROPEAN MEDICINES AGENCY LA PRESENTAZIONE DELLA RICHIESTA DI AUTORIZZAZIONE ALL’IMMISSIONE IN COMMERCIO PER ARS-1 (SPRAY NASALE A BASE DI EPINEFRINA)2020-11-30T13:00:57Z<![CDATA[RECORDATI: ACCETTATA DALLA EUROPEAN MEDICINES AGENCY LA PRESENTAZIONE DELLA RICHIESTA DI AUTORIZZAZIONE ALL’IMMISSIONE IN COMMERCIO PER ARS-1 (SPRAY NASALE A BASE DI EPINEFRINA)]]>https://www.globenewswire.com/news-release/2020/11/30/2136491/0/en/RECORDATI-MARKET-AUTHORIZATION-APPLICATION-FOR-ARS-1-EPINEPHRINE-NASAL-SPRAY-ACCEPTED-BY-EUROPEAN-MEDICINES-AGENCY.html?f=22&fvtc=4&fvtv=31314RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY2020-11-30T13:00:57Z<![CDATA[RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY]]>https://www.globenewswire.com/news-release/2020/10/29/2116899/0/it/RECORDATI-UTILI-IN-CRESCITA-NEI-PRIMI-NOVE-MESI-DEL-2020-RICAVI-0-6-EBITDA-7-1-UTILE-NETTO-RETTIFICATO-12-3.html?f=22&fvtc=4&fvtv=31314RECORDATI: UTILI IN CRESCITA NEI PRIMI NOVE MESI DEL 2020. RICAVI -0,6%, EBITDA +7,1%, UTILE NETTO RETTIFICATO +12,3%2020-10-29T12:16:35Z<![CDATA[RECORDATI: UTILI IN CRESCITA NEI PRIMI NOVE MESI DEL 2020. RICAVI -0,6%, EBITDA +7,1%, UTILE NETTO RETTIFICATO +12,3%]]>https://www.globenewswire.com/news-release/2020/10/29/2116899/0/en/RECORDATI-PROFIT-GROWTH-IN-THE-FIRST-NINE-MONTHS-OF-2020-REVENUES-0-6-EBITDA-7-1-ADJUSTED-NET-INCOME-12-3.html?f=22&fvtc=4&fvtv=31314RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3%2020-10-29T12:16:35Z<![CDATA[RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3%]]>